Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GALK1 | P51570 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898107 | 0.93 | KCNMA1 (0.43) | KCNMA1PKMLMNAALDH1A1USP2 | |
| SCHEMBL427962 | 0.83 | KCNMA1 (0.48) | KCNMA1CNR2 | |
| SCHEMBL424826 | 0.82 | HCAR3 (0.49) | HPGD | |
| SCHEMBL427200 | 0.81 | NAMPT (0.45) | KCNMA1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL7906239 | 0.81 | KCNMA1 (0.37) | KCNMA1ALDH1A1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL425578 | 0.80 | FAAH (0.47) | KCNMA1ALDH1A1HTTMAPTNPSR1 | |
| SCHEMBL424832 | 0.80 | HPGD (0.41) | ALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL426009 | 0.79 | GAA (0.46) | KCNMA1LMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL426112 | 0.79 | MAPT (0.55) | KCNMA1ALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL425936 | 0.78 | KCNMA1 (0.39) | KCNMA1ALDH1A1SMN1; SMN2MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | KCNMA1 3175/4885PKM 1840/4885LMNA 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.